2B30 logo

Xeris Biopharma Holdings DB:2B30 Stock Report

Last Price

€4.85

Market Cap

€737.4m

7D

22.4%

1Y

151.1%

Updated

19 Mar, 2025

Data

Company Financials +

Xeris Biopharma Holdings, Inc.

DB:2B30 Stock Report

Market Cap: €737.4m

2B30 Stock Overview

Engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. More details

2B30 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Rewards

Trading at 16.1% below our estimate of its fair value

Earnings are forecast to grow 60.05% per year

Earnings have grown 13.7% per year over the past 5 years

Risk Analysis

Negative shareholders equity


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Xeris Biopharma Holdings, Inc. Competitors

PharmaSGP Holding

XTRA:PSG

€302.2m

Dermapharm Holding

XTRA:DMP

€2.2b

MPH Health Care

DB:93M1

€95.9m

Apontis Pharma

XTRA:APPH

€95.0m

Price History & Performance

Summary of share price highs, lows and changes for Xeris Biopharma Holdings
Historical stock prices
Current Share PriceUS$4.85
52 Week HighUS$4.85
52 Week LowUS$1.58
Beta1.21
1 Month Change44.31%
3 Month Change57.24%
1 Year Change151.09%
3 Year Change90.79%
5 Year Changen/a
Change since IPO169.22%

Recent News & Updates

Recent updates

Shareholder Returns

2B30DE PharmaceuticalsDE Market
7D22.4%2.0%4.1%
1Y151.1%-10.7%17.2%

Return vs Industry: 2B30 exceeded the German Pharmaceuticals industry which returned -10.7% over the past year.

Return vs Market: 2B30 exceeded the German Market which returned 17.2% over the past year.

Price Volatility

Is 2B30's price volatile compared to industry and market?
2B30 volatility
2B30 Average Weekly Movement7.1%
Pharmaceuticals Industry Average Movement4.2%
Market Average Movement5.4%
10% most volatile stocks in DE Market12.1%
10% least volatile stocks in DE Market2.8%

Stable Share Price: 2B30 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 2B30's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005394John Shannonwww.xerispharma.com

Xeris Biopharma Holdings, Inc., engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.

Xeris Biopharma Holdings, Inc. Fundamentals Summary

How do Xeris Biopharma Holdings's earnings and revenue compare to its market cap?
2B30 fundamental statistics
Market cap€737.35m
Earnings (TTM)-€50.32m
Revenue (TTM)€186.34m

4.2x

P/S Ratio

-15.4x

P/E Ratio

Is 2B30 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2B30 income statement (TTM)
RevenueUS$203.07m
Cost of RevenueUS$36.83m
Gross ProfitUS$166.24m
Other ExpensesUS$221.07m
Earnings-US$54.84m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.36
Gross Margin81.86%
Net Profit Margin-27.00%
Debt/Equity Ratio-783.8%

How did 2B30 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/19 03:38
End of Day Share Price 2025/03/19 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xeris Biopharma Holdings, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chase KnickerbockerCraig-Hallum Capital Group LLC
Robin Garner KalleyCraig-Hallum Capital Group LLC
Oren LivnatH.C. Wainwright & Co.